IP Library Granted Patent US 8,454,964
Granted Patent B2
US 8,454,964 · App. 10/510,655 · Granted Jun 4, 2013

Microparticles comprising carbohydrate beads covalently linked with allergen

Inventors: Hans Groenlund (Lidingoe, SE); Johan Roennelid (Uppsala, SE); Alex Karlsson-Parra (Moelndal, SE); Marianne Van Hage-Hamsten (Bromma, SE); Rudolf Valenta (Theresienfeld, AT); Susanne Vrtala (Vienna, AT); Ursula Wiedermann (Vienna, AT); Dietrich Kraft (Vienna, AT)
Assignee: Biomay AG
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,454,964
App. No.
10/510,655
Granted
Jun 4, 2013
Kind
B2
Abstract

Microparticles are disclosed which comprise a bead essentially consisting of a cross-linked carbohydrate and an antigen covalently linked thereto. The microparticle can be used for the treatment of disorders of the immune system and in diagnostic tests.

Claims (11)

1. A medicament for allergen-specific immunotherapy, said medicament containing a therapeutically effective amount of microparticles in a pharmaceutical formulation suitable for in vivo administration selected from the group consisting of an injectable solution, rectal foam, nasal spray, ointment and plaster, said microparticles consisting of:

(a) a three dimensionally cross-linked agarose bead; and

(b) at least one purified recombinant polypeptide allergen derived from plant pollen bound to said bead by means of a covalent bond between said cross-linked agarose and a reactive group of said allergen,

wherein said medicament is capable of inducing a strong allergen-specific IgG response comparable to that of an equivalent Alum-bound allergen with less granulomatous tissue reactions as compared to said Alum-bound allergen, further wherein the microparticles have a mean diameter that ranges from 0.1 μm to 10 μm.

2. The medicament according to claim 1 , wherein the bead is activated spherical agarose.

3. The medicament according to claIm 1 , wherein the at least one allergen is a grass pollen allergen.

4. The medicament according to claim 1 , wherein the at least one allergen is a timothy grass pollen allergen.

5. The medicament according to claim 1 , wherein the at least one allergen is a Phl p 5b allergen.

6. The medicament according to claim 1 , wherein the microparticles have a mean diameter that ranges from 0.5 μm to 5 μm.

7. The medicament according to claim 1 , wherein the microparticles have a mean diameter of 2 μm.

8. The medicament according to claim 1 , wherein the bead is cyanogen bromide-activated spherical agarose and the at least one allergen is a Phl p 5b allergen.

Assignments (2)
CHANGE OF NAME Recorded May 3, 2013
From: BIOMAY PRODUKTIONS-UND HANDELS-AKTIENGESELLSCHAFT
To: BIOMAY AG
Reel/Frame 030343/0567 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 28, 2005
From: GROENLUND, HANS; ROENNELID, JOHAN; KARLSSON-PARRA, ALEX; HAGE-HAMSTEN, MARIANNE VAN; VALENTA, RUDOLF; VRTALA, SUSANNE; WIEDERMANN, URSULA; KRAFT, DIETRICK
To: BIOMAY PRODUKTIONS- UND HANDELS-AKTIENGESELLSCHAFT
Reel/Frame 015827/0600 →
Priority Claims (1)
EP 02008283 · Apr 22, 2002 · regional
Continuity (1)
Related Publication 20050095298A1 · May 5, 2005